Summary of clinical results

AVENE
Concentré anti-imperfections

Efficacy and safety of CLEANANCE COMEDOMED anti-blemishes concentrate - International observational study

Efficacy and tolerability of CLEANANCE COMEDOMED anti-blemishes concentrate prescribed alone, in combination with anti-acne drug treatments or as a relay, in adolescents and adults with mild to moderate acne
International observational study

Population

4230 subjects from 21 different countries, aged 12 to 25 and with mild to moderate facial acne (GEA score 1 to 3):

  • 50.6% mixed acne (retentional and inflammatory)

  • 36,2% retentional acne

  • 13.2% inflammatory acne

Application of CLEANANCE COMEDOMED anti-blemishes concentrate

2 applications per day on the face for 2 to 3 months 

  • 46,9% as monotherapy
  • 48.3% in combination with drug treatments
  • 4.8% as relay treatments

 

Evaluation criteria

  • Severity of acne (GEA score = Global Evaluation of Acne)
  • Investigator-perceived efficacy investigators
  • Quality of life questionnaire (CADI scale from 0 to 15)
  • Skin tolerance

Results

  • Highly significant improvement in acne severity score at follow-up visit (at 2-3 months): -36.4% (p<0.001, versus Inclusion)
Image 1

Change in acne severity score (GEA) after 2 to 3 months

** p= statistically Highly Significant (p<0.001, versus Inclusion)

 

  • Investigator-perceived anti-infection effect in more than 80% of subjects in each population subgroup at follow-up visit (2-3 months)
Image 2

Investigator-perceived anti-acne efficacy in each subgroup after 2 to 3 months

 

  • Highly significant improvement in quality-of-life score at follow-up visit (at 2 to 3 months): -44.2% (p<0.001, versus Inclusion)
image 3

Evolution of quality of life score after 2 to 3 months

** p= statistically Highly Significant (p<0,001, versus Inclusion)

 

  • Good to very good skin tolerance for 94.7% of subjects

Conclusion

CLEANANCE COMEDOMED anti-blemishes concentrate applied twice daily demonstrated anti-acne efficacy and quality of life benefit in a large international cohort

Good to very good skin tolerance

More summaries of clinical results